Company registration number: 12545380
Unaudited financial statements
for the year ended 30 April 2025
for
Llusern Scientific Ltd
Pages for filing with the Registrar
Company registration number: 12545380
Llusern Scientific Ltd
Balance sheet
as at 30 April 2025
2025 2024
Note £ £ £ £
Fixed assets
Tangible assets 4 43,405 22,102
43,405 22,102
Current assets
Stocks 49,382 56,240
Debtors 84,670 112,360
Cash at bank and in hand 334,671 267,366
468,723 435,966
Creditors: amounts falling due within one
year 		(44,177) (85,603)
Net current assets 424,546 350,363
Total assets less current liabilities 467,951 372,465
Provisions for liabilities (7,542) -
NET ASSETS 460,409 372,465
Capital and reserves
Called up share capital 18 15
Share premium account 1,365,125 769,431
Other reserves 26,611 -
Profit and loss account (931,345) (396,981)
TOTAL EQUITY 460,409 372,465
The company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies for the year ended 30 April 2025.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities to comply with the Companies Act 2006 in respect to accounting records and the preparation of financial statements.
1
Company registration number: 12545380
Llusern Scientific Ltd
Balance sheet - continued
as at 30 April 2025
The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
In accordance with Section 444 of the Companies Act 2006, the Profit and loss account has not been delivered to the Registrar.
These financial statements were approved by the Board of directors and authorised for issue on 2 September 2025 and signed on its behalf by:
Mr M Lewis, Director
2 September 2025
2
Llusern Scientific Ltd
Notes to the financial statements
for the year ended 30 April 2025
1 Company information
Llusern Scientific Ltd is a private company registered in England and Wales. Its registered number is 12545380. The company is limited by shares. Its registered office is Cardiff Edge, Longwood Drive, Cardiff, CF14 7YT.
2 Accounting policies
Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” including the provisions of Section 1A “Small Entities” and the Companies Act 2006. The financial statements have been prepared under the historic cost convention.
Going concern
In preparing these financial statements, the directors have assessed whether there are any material uncertainties related to events or conditions that cast significant doubt upon the company's ability to continue as a going concern. In making this assessment, the directors take into account all available information about the future which is at least 12 months from the date that the financial statements are authorised for issue.
The directors consider that the company has adequate resources to continue in business for the foreseeable future and that it is appropriate to adopt the going concern basis in preparing the financial statements.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, Value Added Tax and other sales taxes.
Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
Plant and machinery etc.:
Plant and machinery - 25% straight line
Fixtures & fittings - 25% straight line
Computer equipment - 25% and 33% straight line basis
Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
3
Llusern Scientific Ltd
Notes to the financial statements - continued
for the year ended 30 April 2025
2 Accounting policies - continued
Taxation
Taxation for the year comprises current and deferred taxation. Tax is recognised in the Profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
Current or deferred taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred taxation
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that been enacted or substantively enacted by the balance sheet date and that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probably that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit and loss in the period to which they relate.
3 Average number of employees
During the year the average number of employees was 8 (2024 - 4).
4 Tangible fixed assets
Plant and
machinery
etc.
£
Cost
At 1 May 2024 25,296
Additions 29,328
At 30 April 2025 54,624
Depreciation
At 1 May 2024 3,194
Charge for year 8,025
At 30 April 2025 11,219
4
Llusern Scientific Ltd
Notes to the financial statements - continued
for the year ended 30 April 2025
4 Tangible fixed assets - continued
Net book value
At 30 April 2025 43,405
At 30 April 2024 22,102
5 Critical accounting judgements and estimates
The company issued shares to employees constituting share based payments. FRS 102 requires the
company to recognise the fair value of the equity instruments as an additional cost. The fair value of the
shares issued has been derived using the entity-specific observable market data. The total additional
costs recognised in the profit and loss in respect of these share based payments is £26,611 (2024 -
£Nil). There are no other key sources of estimation identified by management other than those detailed
in these accounting policies.
6 Share capital
Allotted, issued and fully paid

During the year, the company issued the following shares,
On 13 December 2024, 6,896 Ordinary shares of £0.0001 each, having an aggregate nominal value of £0.69, were allotted for an aggregate consideration of £23.19
On 13 December 2024, 4,311 A2 shares of £0.0001 each, having an aggregate nominal value of £0.43, were allotted for an aggregate consideration of £23.19
On 17 December 2024, 10,778 A1 shares of £0.0001 each, haing an aggregate nominal value of £1.08, were allotted for an aggregate consideration of £23.19
On 17 January 2025, 862 Ordinary shares of £0.0001 each, having an aggregate nominal value of £0.09, were allotted for an aggregate consideration of £23.19
On 17 January 2025, 4,311 A2 shares of £0.0001 each, having an aggregate nominal value of £0.43, were allotted for an aggregate consideration of £23.19

7,758 Ordinary shares of 0.0001 each - £0.78 (2024:£1.76)
8,622 A2 shares of 0.0001 each - £0.86 (2024:£1.41)
10,778 A1 shares of 0.0001 each - £1.08 (2024:£1.76)
7 Share-based payment transactions
Share options

Outstanding at the beginning of the period -
Granted during the period 15,739
Exercised during the period -
Outstanding at the end of the period 15,739

The total charge for the year relating to employee share based payment plans was £20,999 (2024: £Nil) in accorance with provisions of FRS 102 (Section 1A).

On 18 June 2024, the company commenced the operation of an Enterprise Management Incentive scheme (EMI). At 30 April 2025, 15,739 (2024: nil) EMI options remained in issue. These options have an excericise price of between £5.79 per share.
5